A Look At Tenet Healthcare (THC) Valuation After Earnings Beat And Softer Guidance Update

Tenet Healthcare (THC) is back in focus after reporting quarterly revenue growth of 9% year on year, topping analysts’ expectations on both revenue and full year EPS despite relatively weaker guidance versus peers.

See our latest analysis for Tenet Healthcare.

Despite a 3.3% one day share price decline and a 14.2% 30 day share price pullback to US$195.24, Tenet Healthcare still carries a 1 year total shareholder return of 57.7% and a 5 year total shareholder return of 258.8%. This suggests that longer term momentum has remained strong even as sentiment cools after the earnings rally and a series of executive retirement announcements.

If Tenet’s move has you thinking about other opportunities in healthcare, it could be an interesting moment to scan for companies using 31 healthcare AI stocks.

With Tenet trading at US$195.24 and sitting on strong 1 year and multi year returns, but flagged as around 30% above an intrinsic value estimate, investors may need to consider whether there is still an attractive entry point or whether the market has already priced in future growth.

Most Popular Narrative: 18.9% Undervalued

According to the most followed narrative, Tenet Healthcare’s fair value of $240.60 sits well above the last close at $195.24, pointing to a material gap that investors are watching closely.

Tenet Healthcare is no longer just a hospital operator. It is evolving into a broader healthcare platform built around efficiency, integration, and long-term patient management. The growing importance of behavioral health strengthens that model rather than complicating it.

Read the complete narrative.

Curious what supports that higher valuation anchor? The narrative leans heavily on outpatient scale, behavioral health integration, and margin potential from a more efficient mix of services.

Result: Fair Value of $240.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh risks, such as reimbursement pressure on US$21.31b in revenue and execution challenges as Tenet balances hospital and ambulatory growth priorities.

Find out about the key risks to this Tenet Healthcare narrative.

Next Steps

Mixed messages in the data so far? If you want to move quickly and build your own view on both the upside and the downside, start by weighing these 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If Tenet has sharpened your interest, do not stop here. Use screeners to spot other opportunities before they move without you.

• Target quality at a discount by scanning for companies in the 58 high quality undervalued stocks that may offer a more compelling balance between price and fundamentals.
• Prioritise staying power by checking out the solid balance sheet and fundamentals stocks screener (41 results) for businesses with robust financial footing and fewer balance sheet surprises.
• Hunt for potential future standouts using the screener containing 23 high quality undiscovered gems that spotlight less followed names with solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com